PL3689351T3 - Pochodna chinoliny i zastosowanie jej jako inhibitor kinazy tyrozynowej - Google Patents
Pochodna chinoliny i zastosowanie jej jako inhibitor kinazy tyrozynowejInfo
- Publication number
- PL3689351T3 PL3689351T3 PL18862179.1T PL18862179T PL3689351T3 PL 3689351 T3 PL3689351 T3 PL 3689351T3 PL 18862179 T PL18862179 T PL 18862179T PL 3689351 T3 PL3689351 T3 PL 3689351T3
- Authority
- PL
- Poland
- Prior art keywords
- application
- tyrosine kinase
- kinase inhibitor
- quinoline derivative
- quinoline
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710900497 | 2017-09-28 | ||
| CN201810732319 | 2018-07-05 | ||
| PCT/CN2018/106674 WO2019062637A1 (zh) | 2017-09-28 | 2018-09-20 | 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3689351T3 true PL3689351T3 (pl) | 2023-03-20 |
Family
ID=64813340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18862179.1T PL3689351T3 (pl) | 2017-09-28 | 2018-09-20 | Pochodna chinoliny i zastosowanie jej jako inhibitor kinazy tyrozynowej |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11161817B2 (pl) |
| EP (1) | EP3689351B1 (pl) |
| JP (1) | JP7177829B2 (pl) |
| CN (1) | CN109134365B (pl) |
| ES (1) | ES2932805T3 (pl) |
| PL (1) | PL3689351T3 (pl) |
| WO (1) | WO2019062637A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019062637A1 (zh) | 2017-09-28 | 2019-04-04 | 南京明德新药研发股份有限公司 | 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用 |
| CN111592538A (zh) * | 2019-02-21 | 2020-08-28 | 南京明德新药研发有限公司 | 作为ret抑制剂的脂肪环衍生物 |
| JP2022524629A (ja) * | 2019-03-15 | 2022-05-09 | 重▲慶▼医葯工▲業▼研究院有限責任公司 | 抗腫瘍薬の調製におけるキノリン誘導体と免疫調節剤の組み合わせの使用 |
| CN117945999B (zh) * | 2020-01-19 | 2025-08-22 | 重庆医药工业研究院有限责任公司 | 一种氟伐替尼或甲磺酸盐的晶型及其制备方法 |
| CN113480479B (zh) * | 2021-08-12 | 2022-08-02 | 上海爱博医药科技有限公司 | 脲类多靶点酪氨酸激酶抑制剂及其医药应用 |
| CN116410133B (zh) * | 2021-12-29 | 2026-07-03 | 重庆医药工业研究院有限责任公司 | 一种氟伐替尼氢溴酸盐及其制备方法 |
| CN115215799B (zh) * | 2022-08-12 | 2024-05-31 | 上海爱博医药科技有限公司 | 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| AU2006217738A1 (en) | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| CN101311166B (zh) | 2007-05-21 | 2011-03-09 | 李萍 | 酪氨酸激酶抑制剂及其制备药物的用途 |
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| EP2704717A1 (en) * | 2011-05-02 | 2014-03-12 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
| WO2016161952A1 (zh) | 2015-04-07 | 2016-10-13 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
| WO2019062637A1 (zh) | 2017-09-28 | 2019-04-04 | 南京明德新药研发股份有限公司 | 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用 |
-
2018
- 2018-09-20 WO PCT/CN2018/106674 patent/WO2019062637A1/zh not_active Ceased
- 2018-09-20 PL PL18862179.1T patent/PL3689351T3/pl unknown
- 2018-09-20 JP JP2020517877A patent/JP7177829B2/ja active Active
- 2018-09-20 ES ES18862179T patent/ES2932805T3/es active Active
- 2018-09-20 US US16/651,521 patent/US11161817B2/en active Active
- 2018-09-20 EP EP18862179.1A patent/EP3689351B1/en active Active
- 2018-09-28 CN CN201811140279.8A patent/CN109134365B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019062637A1 (zh) | 2019-04-04 |
| JP7177829B2 (ja) | 2022-11-24 |
| EP3689351B1 (en) | 2022-11-02 |
| US11161817B2 (en) | 2021-11-02 |
| CN109134365A (zh) | 2019-01-04 |
| JP2020535188A (ja) | 2020-12-03 |
| CN109134365B (zh) | 2019-05-31 |
| EP3689351A1 (en) | 2020-08-05 |
| US20200262791A1 (en) | 2020-08-20 |
| EP3689351A4 (en) | 2020-08-19 |
| ES2932805T3 (es) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| IL268004B (en) | History of tyrosine amide as rho-kinase inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| EP3293177A4 (en) | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| IL275207A (en) | An oxyfluoropiperidine derivative as a kinase inhibitor | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| EP3250192A4 (en) | Compositions and methods of using tyrosine kinase inhibitors | |
| IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
| ZA201900606B (en) | Novel pyrazole derivative as alk5 inhibitor and uses thereof | |
| PL3447051T3 (pl) | Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| IL266840A (en) | History of tyrosine and preparations containing them | |
| EP3284746A4 (en) | Preparation and use of kinase inhibitor | |
| EP3511327A4 (en) | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | |
| IL272887A (en) | A pharmaceutical preparation containing a selective inhibitor of FGFR tyrosine kinase | |
| EP3699177A4 (en) | METHOD OF MANUFACTURING A TYROSINKINAS INHIBITOR AND INTERMEDIATE THEREOF | |
| HK40026701A (en) | Kinase inhibitors and uses thereof | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
| HK1263283A1 (en) | Crmp2 sumoylation inhibitors and uses thereof |